CRISPR Therapeutics (NASDAQ:CRSP) saw its analyst rating upgraded to 'Hold' by Wall Street Zen, following a recent wave of mixed-to-positive sentiment from major institutions. Citigroup restated its rating to 'market outperform,' while Sanford C. Bernstein raised its price target to $56.00 and Evercore set an...
Simply Wall St analysis suggests CRISPR Therapeutics (CRSP) shares are trading at US$54.09, representing a significant discount to its estimated fair value of US$177.40 based on a discounted cash flow (DCF) model projecting future cash flows. The stock has demonstrated solid short-term momentum with a...
CRISPR Therapeutics (NASDAQ: CRSP) shares have recently declined, trading around $49.37 after dropping 5% in the past week and 8% year-to-date. Despite this short-term weakness, investment firm Piper Sandler has raised its price target to $110, implying over 120% upside potential from current levels. The...
CRISPR Therapeutics (NASDAQ: CRSP) stock has experienced significant volatility as the market evaluates its transition from a clinical-stage biotech to a commercial entity. While the company achieved a major milestone in late 2023 with the regulatory approval of CASGEVY, the first CRISPR-based treatment for sickle...
Metagenomi Therapeutics, Inc. (NASDAQ: MGX), an in vivo genome editing company headquartered in Emeryville, California, reported its first quarter 2026 financial results and key business milestones on May 11, 2026. The company maintains a substantial cash position with $140.2 million in cash, cash equivalents, and...
CRISPR Therapeutics AG, trading under the ticker CRSP, is currently identified as a trending stock on Zacks.com following increased search volume and market attention. The article analyzes the stock's recent performance, noting that shares rose 1.4% over the past month compared to an 11% gain...
CRISPR Therapeutics AG (CRSP) is described as a trending stock on Zacks.com, with shares having gained 1.4% over the past month compared to the S&P 500's 11% gain and contrasting with its medical genetics industry peers which lost 1%. The article focuses on fundamental factors...
Healthcare sector analyst activity is the primary focus of this article, which details new ratings and price targets for three specific stocks: Dexcom (DXCM), Ironwood Pharma (IRWD), and Crispr Therapeutics AG (CRSP). The content provides specific data points regarding Wells Fargo analyst recommendations for each...
CRISPR Therapeutics AG (CRSP) reported first-quarter earnings that missed both analyst estimates for loss and revenue. The company posted an adjusted loss of $1.28 per share, compared to the consensus expectation of a $1.14 loss and its own prior period's loss of $1.58. Revenue came...
Morningstar, Inc. (NASDAQ: MORN) has announced a significant rebranding milestone following its acquisition of the Center for Research in Security Prices (CRSP) from the University of Chicago. The company will officially rename the CRSP Market Indexes to Morningstar Indexes, effectively integrating these assets into its...
